Joshi, R., Zardavas, D., Ragone, A., Chica-Duque, S., Wang, Y., Liu, Y., Liu, Y., Cao, Y., Tine, B. A. V. (2025). A first-in-human, phase 1a/b, dose-escalation/expansion study of BG-68501, a selective CDK2 inhibitor, as monotherapy or in combination with fulvestrant for patients with HR+/HER2- breast cancer and other advanced solid tumors: First disclosure of clinical data.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.3115